title: Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
abstract: As part of a program to identify new compounds that have activity against orthopoxviruses, a number of 4'-thionucleosides were synthesized and evaluated for their efficacies against vaccinia and cowpox viruses. Seven compounds that were active at about 1 microM against both viruses in human cells but that did not have significant toxicity were identified. The 5-iodo analog, 1-(2-deoxy-4-thio-beta-d-ribofuranosyl)-5-iodouracil (4'-thioIDU), was selected as a representative molecule; and this compound also inhibited viral DNA synthesis at less than 1 microM but only partially inhibited the replication of a recombinant vaccinia virus that lacked a thymidine kinase. This compound retained complete activity against cidofovir- and ST-246-resistant mutants. To determine if this analog had activity in an animal model, mice were infected intranasally with vaccinia or cowpox virus and treatment with 4'-thioIDU was given intraperitoneally or orally twice daily at 50, 15, 5, or 1.5 mg/kg of body weight beginning at 24 to 120 h postinfection and was continued for 5 days. Almost complete protection (87%) was observed when treatment with 1.5 mg/kg was begun at 72 h postinfection, and significant protection (73%) was still obtained when treatment with 5 mg/kg was initiated at 96 h. Virus titers in the liver, spleen, and kidney were reduced by about 4 log(10) units and about 2 log(10) units in mice infected with vaccinia virus and cowpox virus, respectively. These results indicate that 4'-thioIDU is a potent, nontoxic inhibitor of orthopoxvirus replication in cell culture and experimental animal infections and suggest that it may have potential for use in the treatment of orthopoxvirus infections in animals and humans.
authors.affiliation: Department of Pediatrics, University of Alabama School of Medicine, Birmingham, 35233, USA. kern@uab.edu
authors.forename: Earl R
authors.initials: ER
authors.lastname: Kern
authors.forename: Mark N
authors.initials: MN
authors.lastname: Prichard
authors.forename: Debra C
authors.initials: DC
authors.lastname: Quenelle
authors.forename: Kathy A
authors.initials: KA
authors.lastname: Keith
authors.forename: Kamal N
authors.initials: KN
authors.lastname: Tiwari
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Maddry
authors.forename: John A
authors.initials: JA
authors.lastname: Secrist
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D015605:Cowpox / Q000188:drug therapy; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D004279:DNA, Viral / Q000096:biosynthesis / Q000235:genetics; D024882:Drug Resistance, Viral; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D009705:Nucleosides / Q000627:therapeutic use*; D018155:Orthopoxvirus; D011213:Poxviridae Infections / Q000188:drug therapy* / Q000821:virology; D013329:Structure-Activity Relationship; D014615:Vaccinia / Q000188:drug therapy; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D009705:Nucleosides; D001616:beta-Galactosidase